Loading...
  • cisplatin
  • The BEP regimen is bleomycin at 20 U/m 2 (not to exceed 30 U) IV q3wk for 4 courses, etoposide at 75 mg/m 2 IV on days 1-5 q3wk for 4 courses, and cisplatin at 20 mg/m 2 IV on days 1-5 q3wk for 4 courses. (medscape.com)
  • novel
  • The present study investigates the effect of a novel 5-HT 3 receptor antagonist 3-methoxy- N - p -tolylquinoxalin-2-carboxamide (QCM-4) on several pathogenic markers of depression associated with obesity such as plasma insulin resistance, hippocampal cyclic adenosine monophosphate (cAMP), brain-derived neurotrophic factor (BDNF), serotonin (5-HT) concentrations, hippocampal neuronal damage, and p53 protein expression in high-fat-diet (HFD)-fed mice. (springer.com)
  • dose
  • Based on tolerability the dose may be reduced by 5 mg/day. (clinicaltrials.gov)
  • The dose may then be decreased to 5 mg/day or increased to 20 mg/day according to the responses and symptoms of the participants. (clinicaltrials.gov)
  • Neither dose increase from 5 to 20 mg nor dose reduction from 20 to 5 mg will be allowed. (clinicaltrials.gov)
  • Target dose is 10 mg/day, however, the dose can be down- or uptitrated to 5, 15, or 20 mg/day. (clinicaltrials.gov)
  • The maximum observed effect (Emax), assessed by the maximum observed concentration of 5-HT in plasma measured at Baseline, after a single dose (Day 1) and after multiple doses (Day 14). (clinicaltrials.gov)
  • The time to reach maximum pharmacodynamic effect (Emax) was assessed by the time to maximum concentration of 5-HT in plasma at Baseline, after a single dose (Day 1) and after multiple doses (Day 14). (clinicaltrials.gov)
  • The maximum observed effect (Emax), assessed by the maximum concentration of 5-HT in cerebrospinal fluid (CSF) measured at Baseline, after a single dose (Day 1) and after multiple doses (Day 14). (clinicaltrials.gov)
  • plasma
  • QCM-4 showed poor sensitivity for plasma glucose, improved insulin sensitivity, increased hippocampal cAMP, BDNF, and 5-HT concentrations. (springer.com)
  • Area Under the Effect Curve From Time Zero to 24 Hours Postdose of 5-hydroxytryptamine (5-HT) in Plasma [ Time Frame: Day -1 (Baseline), Day 1 and Day 14. (clinicaltrials.gov)
  • Maximum Concentration of 5-HT in Plasma [ Time Frame: Day -1 (Baseline), Day 1 and Day 14. (clinicaltrials.gov)
  • Time to Maximum Concentration of 5-HT in Plasma [ Time Frame: Day -1 (Baseline), Day 1 and Day 14. (clinicaltrials.gov)
  • Note: Plasma samples for 5-HIAA on Day -1 were lost in shipping. (clinicaltrials.gov)
  • drug
  • The activity of the lead compounds can be improved by rational drug design (based on pharmacophore analysis or co-crystal structures with the receptor) and medicinal chemistry. (frontiersin.org)
  • years
  • Do not give them to children under 5 years of age. (emedicinehealth.com)
  • A female patient, 61 years old, 5 foot 4 inches tall, 135 pounds, will receive oral capecitabine therapy as a component of the chemotherapeutic regimen to treat breast cancer. (brainscape.com)